Thursday, October 18, 2012

New 'Scarless' Surgery Takes out Tumors Through Natural Skull Opening

A technique developed by Johns Hopkins surgeons is providing a new route to get to and remove tumors buried at the base of the skull: through the natural hole behind the molars, above the jawbone and beneath the cheekbone.
In a report detailing the novel surgery, published in the October 2011 issue of The Laryngoscope, the surgeons say the procedure, already performed in seven patients, yields faster recovery and fewer complications than traditional approaches. And, because the incisions are made inside the cheek, there are no visible scars.
Kofi Boahene, M.D., an assistant professor of facial plastic and reconstructive surgery and otolaryngology-head and neck surgery at the Johns Hopkins University School of Medicine, says the idea for the new approach came to him when a 20-year-old female patient previously treated for a brain tumor developed a new tumor deep in the skull base.
Traditional surgeries to remove skull base tumors require incisions through the face and bone removal, which can sometimes be disfiguring. Additionally, these operations can harm facial nerves, leading to paralysis that affects facial expressions and days or weeks of hospitalization and recovery. Boahene said he was gazing at a skull model in his office, considering options to spare his patient from another traditional surgery. "I looked at the 'window" that already exists in the skull, above the jawbone and below the cheekbone and realized this was an access route not previously recognized for this kind of surgery," he said.
Knowing there was always the option of switching to the traditional approach while trying the new approach, Boahene and his colleagues performed the new procedure on his patient last year. The expected surgery time shrunk from six hours to two. Additionally, the patient was able to leave the hospital the next day and return to college, with no visible evidence that she had surgery performed.
The report in The Laryngoscope describes details of the surgeries on three of the seven patients Boahene and his colleagues have thus far treated. Besides benefits for patients, he and his colleagues note, the new procedure is significantly less complicated for surgeons to perform, provides excellent visualization of the skull base area, and could potentially save health care dollars due to patients' shorter hospital stays.
Not all patients are candidates for this procedure, Boahene cautions. It isn't an option for those with very large skull base tumors or those with tumors that wrap around blood vessels. For these patients, traditional skull base surgery is still the best choice, he says.
In the future, he and his colleagues plan to try the new procedure using a surgical robot, which could provide even better visualization for surgeons and further reduce chances of complications for patients.

Study reveals genomic similarities between breast and ovarian cancers

One subtype of breast cancer shares many genetic features with high-grade serous ovarian cancer, a cancer that is very difficult to treat, according to researchers supported by the National Institutes of Health. The findings suggest that the two cancers are of similar molecular origin, which may facilitate the comparison of therapeutic data for subtypes of breast and ovarian cancers.
The researchers, using data generated as part of The Cancer Genome Atlas (TCGA), described new insights into the four standard molecular subtypes based on a comprehensive characterization of samples from 825 breast cancer patients.
The study, a collaborative effort funded by the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both part of NIH, was published online Sept. 23, 2012, and in print Oct. 4, 2012, in the journal Nature.
“TCGA’s comprehensive characterization of their high-quality samples allows researchers an unprecedented look at these breast cancer subgroups,” said NIH Director Francis S. Collins, M.D., Ph.D.
Microscopic view of breast cancer cells with cell nuclei stained blue and dots responding to overproduction of the HER2 protein lit up in bright red
Breast cancer cells seen under the microscope, with the HER2 protein, which can trigger cell growth responses, lit up in bright red
Analyses of genomic data have confirmed that there are four primary subtypes of breast cancer, each with its own biology and survival outlooks.  These TCGA findings are based on a large number of breast cancer specimens that capture a complete view of the genomic alterations.  The four groups are called intrinsic subtypes of breast cancer: HER2-enriched (HER2E), Luminal A (LumA), Luminal B (LumB) and Basal-like.  A fifth type, called Normal-like, was observed, but because of small numbers (only eight specimens) the researchers were unable to rigorously study it.
The TCGA Research Network uncovered marked genomic similarities between the Basal-like subtype and serous ovarian cancer. The mutation spectrum, or types and frequencies of genomic mutations, were largely the same in both cancer types. Further analyses identified several additional common genomic features, such as gene mutation frequency, suggesting that diverse genomic aberrations can converge into a limited number of cancer subtypes.
Computational analyses show that Basal-like breast cancer and serous ovarian cancer might both be susceptible to agents that inhibit blood vessel growth, cutting off the blood supply to the tumor, as well as to compounds that target DNA repair, which include chemotherapy drugs such as cisplatin.
The Basal-like subgroup has also been called Triple Negative Breast Cancer because many, though not all, Basal-like tumors are negative when tested for three receptors: the estrogen receptor, the progesterone receptor and human epidermal growth factor receptor 2 (HER2). These receptors can trigger potent cell growth responses and act like a nametag, identifying the cell to the environment. The absence of these receptors means that treatments that target them will most likely be ineffective.
“The molecular similarity of one of the principal subtypes of breast cancer to that found in ovarian cancer gives us additional leverage to compare treatments and outcomes across these two cancers,” noted Harold Varmus, M.D., NCI director.  “This treasure trove of genetic information will need to be examined in great detail to identify how we can use it functionally and clinically.”
According to the World Health Organization, there are approximately 1.3 million new cases of breast cancer and 450,000 deaths worldwide annually. Breast cancer is the most common cancer among women. The majority of cases are sporadic, meaning there is not a family history of breast cancer, as opposed to genetic, where genes predispose a person to the disease.  Men can also develop breast cancer, but it accounts for less than 1 percent of breast cancer cases.
Breast cancer tumors that have the HER2 receptor are called HER2-positive, and those that don't are called HER2-negative. When researchers analyzed the genomic findings from tumors determined to be HER2-positive by standard cellular tests, they found that only half of the samples could be characterized as belonging to the HER2E subtype. The other half were characterized as Luminal subtypes, suggesting that there are at least two types of clinically defined HER2-positive tumors.
In general, the Luminal subtypes had the lowest overall mutation rate, but by contrast, had the largest number of genes observed to be significantly mutated. This suggests that each of the genes identified as significantly mutated in the Luminal subtypes is more likely to be important in fueling cancer progression. The Luminal subtypes are characterized by the specific expression signature of multiple so-called transcription-factor genes, including ESR1, GATA3, FOXA1, XBP1 and cMYB. These genes have a complex interaction, cooperating in an orchestrated series of activations. GATA3 and FOXA1 are frequently mutated, but those mutations are mutually exclusive, meaning that mutations were observed in either GATA3 or FOXA1 but never in both. However, ERS1 and XBP1 are highly expressed but infrequently mutated.
The scale of the TCGA program allows researchers to perform the integrative analyses that detect these complex patterns of genomic changes and interactions. This close inspection of the cancer genome has led to a deeper understanding of the mutations essential for cancer progression, and several new candidates were identified in this study. The authors hope that discovery of these mutations will be a crucial step toward improving breast cancer therapies.
This publication focuses on the discoveries made through a combined analysis involving data from 825 breast cancer cases, which are freely available in the TCGA Data Portal, with several hundred more cases to come.
“The data generated by the TCGA program comprise a vast resource that investigators will be analyzing for years to come.  The resource of information about breast cancer genomes will undoubtedly fuel myriad discoveries by the cancer research community,” said Eric D. Green, M.D., Ph.D., NHGRI director.
So far, The Cancer Genome Atlas Research Network has published analyses on these cancers:
• glioblastoma multiforme (http://cancergenome.nih.gov/newsevents/newsannouncements/news_9_4_2008)
• ovarian serous adenocarcinoma (http://cancergenome.nih.gov/newsevents/newsannouncements/ovarianpaper)
• colorectal adenocarcinoma
(http://www.cancer.gov/newscenter/newsfromnci/2012/TCGAcolorectal)
• lung squamous cell carcinoma
(http://www.cancer.gov/newscenter/newsfromnci/2012/LungSquamousTCGA)

Sildenafil - Multi Faceted Personality

Did any one ever think that "a sexual enhancer" can be a life saving drug for some one?

Few facts about Viagra:
Sildefanil was synthesized by a group of pharmaceutical chemists at Pfizers' research facility in England. It was initially studied for use in hypertension and angina.
Phase I clinical trials suggested that the drug had little effect on angina, but that it could induce marked penile erections. Pfizer therefore decided to market it for erectile dysfunction, rather than for angina. The drug was patented in 1996, approved for use in erectile dysfunction by the US FDA on March 27, 1998, becoming the first oral treatment approved to treat erectile dysfunction in the United States.
Oral Sildenafil in Infants With Persistent Pulmonary Hypertension of the Newborn:
•          Persistent pulmonary hypertension (PPHN) occurs in as many as 6.8 of 1000 live births.
•          Mortality is ∼10% to 20% with high-frequency ventilation,
•          Sildenafil is a phospho diesterase inhibitor type 5 that selectively reduces pulmonary vascular resistance.
Treatment of Severe Altitude Sickness using Viagra:  
•          High altitude can sometimes cause illness, especially in people with existing heart and lung problems. The thinner air or lack of oxygen at higher altitudes can cause blood vessels to constrict. When this occurs within the lungs, the constriction of blood vessels can put more force on the heart, leading to life-threatening heart failure.
•          High-altitude pulmonary edema (HAPE) occurs when high altitude and low air pressure causes fluid to leak from blood vessels and builds up in the lungs, interfering with oxygen exchange.. HAPE has a mortality rate of 44% if untreated. It's triggered by intense physical exertion at high altitudes that people aren't accustomed to.
•          Viagra works by relaxing blood vessels, allowing more blood to flow freely through vessels. The researchers used this drug to block the effects of high altitude on blood vessels on the lung.
Sildenafil in the treatment of pulmonary arterial Hypertension:
•          Pulmonary arterial hypertension (PAH) is a progressive, and often fatal, debilitating disorder.  The clinical hallmarks of this disease include: 1) progressive breathlessness 2) exertion limitation and 3) frequent decline and failure of the right ventricle.
•          The increased pulmonary artery pressure found in PAH is due to disturbances in key vascular mediator pathways including relative deficiencies of vasodilators
•          Sildenafil is a selective Phosphodiesterase-5 inhibitor that has been reported to be a potent pulmonary vasodilator. Sildenafil selectively inhibits phosphodiesterase 5 (PDE5 is abundant in pulmonary and penile tissue) which leads to stabilization of cyclic guanosine monophosphate (cGMP).  cGMP is a second messenger of nitric oxide (NO). Stabilization of cGMP results in increasing nitric oxide (NO) at the tissue level leading to pulmonary vessel vasodilatation.
•          Sildenafil administered orally has been shown to have beneficial effects in patients with PAH. 
On a whole the viagra(Sildefanil) is found to be a potent life saver in many aspects and doctors found it to be a very attractive drug for cardiac conditions and lowering blood pressure and noticed that when they prescribe Viagra to patients with a heart condition it actually improves their heart condition as well as their erectile dysfunction.
•          The problem doctors see in premature babies with breathing difficulties is - although oxygen can be blown into their lungs to help them, there isn't enough blood supply to various areas of the lungs to take the oxygen around the rest of the body. What Sildenafil does is open up the blood vessels so they can capture the oxygen and take it around the body
Thus Sildenafil or Viagra as it is popularly known world over, has shown multi faceted personality over the years and helped the medical community in combating severe diseases and ailments.  As time passes, research may unfold cures to many more ailments through the use of Viagra.
 
 

Fecal Therapy!!

The procedure, also known as fecal biotherapy, involves the transfer of saline-diluted fecal matter into a patient’s GI tract through an enema or nasoduodenal catheter. Repopulating the gut with healthy bacteria in this way can dramatically reduce symptoms and put some UC patients into remission, according to small case studies and anecdotal reports. These preliminary findings are raising hopes in the IBD community that this novel treatment could be a possible cure.

McMaster University microbiologist Dr. Michael Surette is the lead investigator for a new CCFC-funded study that will evaluate the effectiveness of fecal transplants in a randomized controlled trial involving 130 UC patients from Ontario at St. Joseph’s Hospital in Hamilton. (The clinical trial is led by Dr. Surette’s co-principal investigators, Dr. Paul Moayyedi and Dr. Christine Lee.)

In an earlier study, the McMaster researchers found that seven of eight UC patients responded to fecal transplants and six patients remained well one year following treatment. “We’re seeing success rates of 80 to 90 per cent. This kind of clinical trial is absolutely essential for a new treatment to become a standard of care,” says Dr. Surette, who holds a Tier 1 Canada Research Chair in Interdisciplinary Microbiome Research and is well known for his research on the complex relationships between bacteria and disease.

A gold-standard clinical trial is needed to prove that fecal transplants are an effective treatment for ulcerative colitis. If the McMaster study shows that a significant number of UC patients are cured or much improved, this would provide the scientific basis for the treatment to be offered widely in major centres across the country. The results are expected within two years.

Another important goal of the CCFC-funded study is to learn more about how and why fecal transplants work, and the critical differences between treatment successes and failures. “There is a huge question about why fecal biotherapy seems to work so well,” says Dr. Surette. “What is the mechanism driving the success rates?”

Researchers believe that an imbalance of harmful bacteria in the gut may be driving the inflammation in ulcerative colitis and that replacing them with helpful bacteria from a healthy donor may reset the patient’s immune system and stop the chronic inflammation.

To investigate this theory and answer these questions, Dr. Surette will be doing sophisticated tests to measure changes in the collective population of helpful and harmful bacteria in the gut in UC patients before and after treatment. (The collective population of helpful and harmful bacteria is known as the microbiome.) “We want to see what bacteria species from the healthy donor get transferred to the patients who are successfully treated and look for differences in the bacteria of patients that fail treatment,” he explains.

This study is unique in that only one to three donors will be used for all the fecal transplants, helping researchers to pinpoint bacteria associated with treatment success or failure.

Learning exactly which microbes from the donor are important will help to make the treatment effective for as many UC patients as possible. This could also lead to more specific targeted therapies in the future with bacteria grown in the lab, for example.

Dr. Surette will look for biomarkers in the intestinal lining of patients as well, which could be used as reliable indicators of the success or failure of treatment. “These biomarkers could help us measure how well the therapy is working and adjust the treatment for each patient to make it more effective. We might be able to better differentiate the disease and determine which patients are the best candidates,” he says.

Despite the “yuck” factor, most patients surveyed say they would choose fecal transplantation as a treatment because it’s more natural than many UC medications.

The McMaster researchers are excited because fecal biotherapy targets the underlying cause of the disease. “Dampening the inflammation with a drug is treating the symptoms and not treating the disease. What’s driving the inflammation is microbial. The immune system is out of kilter. The advantage of changing the microbiome is that it might be a way to reset the immune system. You’re getting at the root cause rather than just the symptoms,” says Dr. Surette.

“This is a very promising therapy, which could potentially be of benefit to many people with ulcerative colitis. This kind of therapy may work in many kinds of inflammatory diseases, including Crohn’s disease.”

New study shows liposuction can tackle lymphedema in head and neck cancer patients

A new study has shown liposuction can be used to treat submental lymphedema in patients who have suffered from head or neck cancer.



The condition often occurs among individuals who have received treatment for these forms of cancer and affects the area under the chin. Fluid builds up and the soft tissues in the neck start to swell, leading to the area not functioning properly and becoming disfigured.



Dr S. Mark Taylor and Dr Maria Brake, of Dalhousie University in Halifax, Nova Scotia, conducted a study on ten patients suffering fromsubmental lymphedema and treated the condition by making a small incision in their necks before using liposuction to remove fat and fluid.



“The procedure is well tolerated under local anaesthesia and in our hands has proven to be very effective, resulting in high patient satisfaction,” the authors stated.



None of those who took part in the study experienced complications and their condition did not reoccur following the procedure.



All patients claimed they would recommend the treatment to others with submental lymphedema as they were pleased with the results.



The report was published in the journal Otolaryngology - Head and Neck Surgery and the authors now plan to offer liposuction to their other head and neck cancer patients

Belly Fat Weight Loss Foods

It is impossible to target a specific area of your body for fat loss. If you're aiming to lose fat from your belly, adopt an overall cardiovascular exercise plan that focuses on burning calories and fat, while also tackling exercises that isolate your core muscles --- both abdominal and lower-back muscles. While eating specifics foods won't, by itself, trim fat from your belly, there are a handful of foods you should incorporate into your diet to help you lose that stubborn belly fat.

Whole Grains and Oats

Although many popular commercial weight-loss diets require you to eliminate carbohydrates almost entirely, eating the right kinds, in moderation, can help you when it comes to losing belly fat. Brown rice and whole grain or whole wheat bread contain fiber and amino acids that can benefit your weight-loss goals. Eating oatmeal in the morning can also help blast belly fat, as the fiber will help stave off late-morning food cravings. Oatmeal also contains vitamins and protein. Avoid the packaged, flavored oatmeals, however; they are loaded with sugar, which will counteract your weight-loss attempts.
 
Protein:
Protein is made up of amino acids, which are the building blocks of muscle tissue and can help burn stored fat in your body. Obtain essential amino acids, which are those that your body does not produce naturally and must be provided through your diet, by eating animal-based foods such as dairy products, meat and eggs. Choose low-fat sources of protein, such as lean cuts of beef, grilled fish and poultry.

Snacks

Keeping healthy snacks on hand to eat between meals will help ensure you don't eat too much, or crave unhealthy foods, when mealtime rolls around. Nuts, such as almonds, make a good snack because they contain amino acids and dietary fiber, which will help you feel fuller longer. Protein shakes also make for a good, belly fat-burning snack. Mix protein powder with skim or 1-percent milk, or add it to a smoothie for a healthy snack loaded with amino acids.

Fruits and Vegetables

Low-carbohydrate weight-loss diets won't allow you many servings of fruits each day, since the carbs and sugars contained therein end up as glycogen and, ultimately, as fat, if your body fails to burn them as energy. Consume fruits in moderation when trying to burn belly fat, but don't remove them from your diet altogether. The vitamins, fiber and amino acids in berries, in particular, can help you reach your goals. Vegetables, particularly dark, leafy greens and broccoli, are low in calories and high in fiber, vitamins and minerals.
 

Tuesday, October 16, 2012

Do you know how are chemical contituents identified, which are specific for each activity????

Plant chemical constituents are specific for each ant every activity and used against disorders and ailments. Do You know how?? If you desire to know more, then post your ideas and share !!!